| Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors S Pal, V Kumar, B Kundu, D Bhattacharya, N Preethy, MP Reddy, ... Computational and structural biotechnology journal 17, 291-310, 2019 | 130 | 2019 |
| Discovery and mechanistic study of tailor-made quinoline derivatives as topoisomerase 1 poison with potent anticancer activity B Kundu, SK Das, S Paul Chowdhuri, S Pal, D Sarkar, A Ghosh, ... Journal of medicinal chemistry 62 (7), 3428-3446, 2019 | 54 | 2019 |
| Topoisomerase I inhibitors: Challenges, progress and the road ahead A Talukdar*, B Kundu*, D Sarkar, S Goon, MA Mondal European Journal of Medicinal Chemistry 236, 114304, 2022 | 39 | 2022 |
| Semisynthetic quercetin derivatives with potent antitumor activity in colon carcinoma A Mukherjee, S Mishra, NK Kotla, K Manna, S Roy, B Kundu, ... ACS Omega 4 (4), 7285-7298, 2019 | 38 | 2019 |
| A chemical switch for transforming a purine agonist for toll-like receptor 7 to a clinically relevant antagonist A Mukherjee, D Raychaudhuri, BP Sinha, B Kundu, M Mitra, B Paul, ... Journal of Medicinal Chemistry 63 (9), 4776-4789, 2020 | 21 | 2020 |
| Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade MR Iyer, B Kundu, CM Wood Expert Opinion on Therapeutic Patents 32 (6), 629-647, 2022 | 20 | 2022 |
| Understanding the riboflavin biosynthesis pathway for the development of antimicrobial agents B Kundu, D Sarkar, N Ray, A Talukdar Medicinal research reviews 39 (4), 1338-1371, 2019 | 18 | 2019 |
| Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9 B Kundu, D Raychaudhuri, A Mukherjee, BP Sinha, D Sarkar, ... Journal of Medicinal Chemistry 64 (13), 9279-9301, 2021 | 16 | 2021 |
| Development of a metabolically stable topoisomerase I poison as anticancer agent B Kundu, D Sarkar, SP Chowdhuri, S Pal, SK Das, BB Das, A Talukdar European Journal of Medicinal Chemistry 202, 112551, 2020 | 9 | 2020 |
| Blocking toll-like receptor 9 signaling with small molecule antagonist A Talukdar, D Ganguly, B Paul, A Mukherjee, S Roy, S Roy, AR Ghosh, ... US Patent US 10,662,177 B2, 2017 | 4 | 2017 |
| Copper-catalyzed selective C–N bond formation with 2-amino, 2-hydroxy and 2-bromo-5-halopyridine S Roy, B Paul, A Mukherjee, B Kundu, A Talukdar RSC advances 7 (70), 44366-44370, 2017 | 4 | 2017 |
| Purine based compounds as toll-like receptor 9 antagonist A Talukdar, D Ganguly, A Mukherjee, B Paul, O Rahaman, B Kundu, ... US Patent US 11,168,084 B2, 2019 | 3 | 2019 |
| Bicycle topoisomerase I inhibiting compounds, process for preparation and use thereof A Talukdar, BB Das, B Kundu, SK Das, CS Paul, D Sarkar, S Pal, ... US Patent US 2021/0246128 A1, 2021 | 2 | 2021 |
| A patent review on aldehyde dehydrogenase inhibitors: an overview of small molecule inhibitors from the last decade B Kundu, MR Iyer Expert Opinion on Therapeutic Patents 33 (10), 651-668, 2023 | | 2023 |
| Sulfonamide derivatives and their use as soluble epoxide hydrolase inhibitors MR Iyer, B Kundu WO Patent WO 2023/114366 A2, 2023 | | 2023 |
| One-Pot Synthesis of Thio-Augmented Sulfonylureas via a Modified Bunte’s Reaction MR Iyer, P Bhattacharjee, B Kundu, N Rutland, CM Wood ACS Omega 2022, 7, 35, 31612–31620, 2022 | | 2022 |
Arindam TalukdarIndian Institute of Chemical Biology- CSIRVerified email at iicb.res.in
